Literature DB >> 16849360

BRAF mutation and gene methylation frequencies of colorectal tumours with microsatellite instability increase markedly with patient age.

B Iacopetta, W Q Li, F Grieu, A Ruszkiewicz, K Kawakami.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16849360      PMCID： PMC1856250          DOI： 10.1136/gut.2006.095455

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

1.  Late onset and high incidence of colon cancer of the mutator phenotype with hypermethylated hMLH1 gene in women.

Authors:  S R Malkhosyan; H Yamamoto; Z Piao; M Perucho
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

2.  P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.

Authors:  H Elsaleh; B Powell; K McCaul; F Grieu; R Grant; D Joseph; B Iacopetta
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

3.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

Authors:  T Watanabe; T T Wu; P J Catalano; T Ueki; R Satriano; D G Haller; A B Benson; S R Hamilton
Journal:  N Engl J Med       Date:  2001-04-19       Impact factor: 91.245

4.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.

Authors:  Wade S Samowitz; Carol Sweeney; Jennifer Herrick; Hans Albertsen; Theodore R Levin; Maureen A Murtaugh; Roger K Wolff; Martha L Slattery
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

Review 5.  Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability.

Authors:  J R Jass; M D Walsh; M Barker; L A Simms; J Young; B A Leggett
Journal:  Eur J Cancer       Date:  2002-05       Impact factor: 9.162

6.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

7.  BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer.

Authors:  Guoren Deng; Ian Bell; Suzanne Crawley; James Gum; Jonathan P Terdiman; Brian A Allen; Brindusa Truta; Marvin H Sleisenger; Young S Kim
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

8.  Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer.

Authors:  A McGivern; C V A Wynter; V L J Whitehall; T Kambara; K J Spring; M D Walsh; M A Barker; S Arnold; L A Simms; B A Leggett; J Young; J R Jass
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

Review 9.  HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences.

Authors:  Jeremy R Jass
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

10.  Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer.

Authors:  John M Carethers; E Julieta Smith; Cynthia A Behling; Lanchinh Nguyen; Akihiro Tajima; Ryan T Doctolero; Betty L Cabrera; Ajay Goel; Christian A Arnold; Katsumi Miyai; C Richard Boland
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682
  10 in total
  5 in total

1.  Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.

Authors:  B Iacopetta; T Watanabe
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

Review 2.  Colorectal cancer in the young, many questions, few answers.

Authors:  Kemal I Deen; Hiroshi Silva; Raeed Deen; Pramodh C Chandrasinghe
Journal:  World J Gastrointest Oncol       Date:  2016-06-15

Review 3.  Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?

Authors:  Barry Iacopetta; Kazuyuki Kawakami; Toshiaki Watanabe
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

4.  Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer.

Authors:  Jashodeep Datta; J Joshua Smith; Walid K Chatila; John C McAuliffe; Cyriac Kandoth; Efsevia Vakiani; Timothy L Frankel; Karuna Ganesh; Isaac Wasserman; Marla Lipsyc-Sharf; Jose Guillem; Garrett M Nash; Philip B Paty; Martin R Weiser; Leonard B Saltz; Michael F Berger; William R Jarnagin; Vinod Balachandran; T Peter Kingham; Nancy E Kemeny; Andrea Cercek; Julio Garcia-Aguilar; Barry S Taylor; Agnes Viale; Rona Yaeger; David B Solit; Nikolaus Schultz; Michael I D'Angelica
Journal:  Clin Cancer Res       Date:  2019-11-12       Impact factor: 12.531

5.  Genetic alterations in colorectal cancer.

Authors:  Tannaz Armaghany; Jon D Wilson; Quyen Chu; Glenn Mills
Journal:  Gastrointest Cancer Res       Date:  2012-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.